Commercialization and Manufacturing Strategy for NMJ Platforms

The contract focuses on providing expert guidance for the commercialization of neuromuscular junction (NMJ)-based botulinum toxin (BoNT) testing platforms. Key components include developing strategies for intellectual property protection, ensuring manufacturing processes can be scaled efficiently, and creating comprehensive plans to facilitate market adoption. This work aims to accelerate the transition of innovative NMJ testing technologies into practical and commercially viable products. Issued by the Department of Health and Human Services under the BARDA office, the subcontract falls under the NAICS code 541611, which pertains to administrative management and general management consulting services. The contract was posted on April 20, 2026, with responses due by May 11, 2026. Performance for this effort is designated for Washington. The contract’s emphasis on commercialization and manufacturing strategy underscores the importance of both technical and market readiness aspects in advancing NMJ testing platforms.